Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors

This study is testing whether injecting a substance called CpG-ODN directly into a tumor stimulates the immune system to attack not only that tumor but also other tumors in the body (a strategy called in-situ vaccination). This approach aims to turn the immune system against cancer without removing the tumor first. **You may be eligible if...** - You have an advanced solid tumor (cancer that has not spread to blood or lymph cells) - You are between 18 and 80 years old - Your life expectancy is more than 3 months **You may NOT be eligible if...** - You have a benign (non-cancerous) tumor - Your life expectancy is less than 3 months - You have a serious medical condition that would make participation unsafe - Other conditions as determined by the study team Talk to your doctor to see if this trial is right for you.